Amneal Pharmaceuticals(NASDAQ) AMRX

Amneal makes and sells many types of medicine people use every day. They help patients with brain and hormone health problems get the treatments they need. The company also delivers medical supplies to government hospitals and pharmacies.

Pills, Shots, and Branded Drugs

• Affordable Medicines: Lower-cost generic versions of common drugs, injectable treatments, and biosimilars, which are near-copies of complex biological medicines.
• AvKARE: Distribution services for medical products and pharmaceuticals primarily serving the U.S. government, military, and retail pharmacies.
• Specialty Branded Products: Branded medications that focus on central nervous system disorders and hormone conditions like Parkinson’s disease and hypothyroidism.

Expanding the Medicine Cabinet

• Agreed to acquire Kashiv BioSciences, LLC in April 2026 to increase its portfolio of complex medicines and clinical-stage products.
• Entered a supply and distribution deal with MSN Laboratories Private Limited in April 2026 for the exclusive rights to a generic bladder treatment.
• Resolved a majority of state and local government legal claims by activating a nationwide settlement for opioid-related litigation in January 2026.
• Lowered the interest rate margins on its multi-billion dollar term loan through a repricing agreement in February 2026.

Control from Lab to Pharmacy

Amneal uses a vertically integrated model, which means it manages everything from its own research and development to manufacturing in the U.S. and India. This structure allows the company to produce a wide range of products, including complex liquids, inhalers, and skin patches.

Recent Financial Performance

• Net income rose to $62.5 million in Q1 2026, a 412.5% increase from Q1 2025.
• Operating income reached $133.5 million in Q1 2026, up from a loss of $10.7 million in Q1 2024.
• Gross profit grew to $320.1 million in Q1 2026, up 25.1% from the previous year.
• Free cash flow worsened to negative $42.6 million in Q1 2026, down from negative $10.9 million in Q1 2025.

Evolution of the Business

Amneal has transitioned from a standard generic drug maker into a diversified pharmaceutical firm with branded medicines and government supply contracts. This evolution reflects a strategy focused on specialized medical products and long-term distribution partnerships.